Human Enhancement Freaks People Out, Study Finds; Designer Babies Might 'Meddle With Nature'
By Ed Cara,
Medical Daily
| 07. 26. 2016
Fond as we are of superheroes on the big screen, most of us would stop short of actually becoming one via technology.
That’s the verdict issued by an extensive survey conducted by the Pew Research Center and released Tuesday. The Center polled over 4,000 Americans on a variety of issues related to advances in biomedical technology that may arrive in the near future — from using implanted brain chips to boost our thinking power to editing the genes of babies to eliminate hereditary flaws and diseases. The representative sample of Americans proved to be more careful than celebratory about these technological leaps.
Sixty-eight percent were somewhat or very worried about gene-editing, as opposed to 49 percent who saw themselves as at least somewhat enthusiastic about the prospect. Sixty-nine percent were also wary of brain implants and 63 percent felt the same about using synthetic blood transfusions to improve our strength, speed, and stamina. A similar percentage were taken aback at the thought of trying these technologies out on themselves or their future children.
"Developments in biomedical technologies are accelerating rapidly, raising...
Related Articles
By Mike McIntire, The New York Times | 01.24.2026
Genetic researchers were seeking children for an ambitious, federally funded project to track brain development — a study that they told families could yield invaluable discoveries about DNA’s impact on behavior and disease.
They also promised that the children’s sensitive...
By Arthur Lazarus, MedPage Today | 01.23.2026
A growing body of contemporary research and reporting exposes how old ideas can find new life when repurposed within modern systems of medicine, technology, and public policy. Over the last decade, several trends have converged:
- The rise of polygenic scoring...
By Danny Finley, Bill of Health | 01.08.2026
The United States Food and Drug Administration (FDA) has a unique funding structure among federal scientific and health agencies. The industries it regulates fund nearly half of its budget. The agency charges companies a user fee for each application
...
By George Janes, BioNews | 01.12.2026
A heart attack patient has become the first person to be treated in a clinical trial of an experimental gene therapy, which aims to strengthen blood vessels after coronary bypass surgery.
Coronary artery bypass surgery is performed to treat...